<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" href="/style.css">
    <title>ReHopefulstat</title>
</head>

<body>
    <header class="top-content">
        <div class="header head-item">Hepion Pharmaceuticals (NASDAQ:HEPA)</div>
        <div class="nav head-item">
            <div class="nav-item"><a href="index.html" class="location">Summary</a></div>
            <div class="nav-item"><a href="factsheet.html">Fact Sheet</a></div>
            <div class="nav-item"><a href="trial.html">Trials</a></div>
        </div>
    </header>

    <section class="preview">
        <div class="preview-item preview-left">"TACKLING CHRONIC LIVER DISEASE:<br>NASH, Hepatitis, Cirrhosis, Liver
            Failure, and Cancer."</div>
        <div class="preview-item preview-right">"Hepion Pharmaceuticals is a clinical stage biopharmaceutical company
            focused on Artificial Intelligence driven therapeutic drug development for the treatment of non-alcoholic
            steatohepatitis, fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases."</div>
    </section>
    <h1 class="watermark">Caprice Yuri</h1>

    <section class="main-content">
        <div class="main-left">
            <h2>Key Mechanism</h2><br>
            <div class="first-letter">Rencofilstat, a cyclophilin inhibitor. Cyclophilin inhibitors demonstrate therapeutic activities in many experimental models.</div><br>
            <div class="first-letter">Rencofilstat has shown to reduce liver fibrosis and tumor development in experimental disease models. </div><br>
            <div class="first-letter">Rencofilstat was found to potently inhibit all cyclophilin isoforms tested — A, B, D, and G.</div><br>
            <div class="first-letter">- Binds to Cylophilin A, reduced inflammatory damage to the liver.</div><br>
            <div class="first-letter">- Blocks the Action of Cylophilin B, reduction in collagen secretions and fibrotic scarring.</div><br>
            <div class="first-letter">- Binds to Cylophilin D, decreases cell death in injured livers. </div><br>
            <div class="first-letter">Cyclosporine A, parent compound of Rencofilstat, an immunosuppressive drug. Which can be used to prevent organ rejection after transplant in a form of oral medication.</div><br>
            <div class="first-letter">- Voclosporin, FDA approved for adult patients with active Lupus Nephritis.</div>
        </div>
        <!-- Main Content Section / Divider -->
        <div class="main-right">
            <h2>Key Events / Overview</h2><br>
            <h3>2023</h3><br>
            <div class="first-letter">January 18 - Anti-Cancer Potential of Rencofilstat with Results from Preclinical Multiple Myeloma Studies.</div>
            <div class="first-letter">January 10 - Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors.</div>
            <!-- Break -->
            <br><h3>2022</h3><br>
            <div class="first-letter">December 5 - Announces Early Completion of Enrollment in Phase 2 ALTITUDE-NASH Liver Function Trial.</div>
            <div class="first-letter">October 26 - Publication of P2A AMBITION Clinical Trial Results.</div>
            <div class="first-letter">October 20 - Publication of Food Effect Study with Rencofilstat.</div>
            <div class="first-letter">September 12 - Initiation of Dosing in P2 ALTITUDE-NASH Liver Function Trial.</div>
            <div class="first-letter">August 31 - Initiation of P2B ASCEND-NASH Trial.</div>
            <div class="first-letter">June 20 - Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of Hepatocellular Carcinoma.</div>
            <div class="first-letter">May 3 - Announces Clinical Collaboration with HepQuant in P2B NASH Trial.</div>
            <div class="first-letter">January 26 - Rencofilstat with an Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity.</div>
            <div class="first-letter">January 6 - Announces USAN Selection of “Rencofilstat” as Nonproprietary Name for CRV431.</div>
            <!-- Break -->
            <br><h3>2021</h3><br>
            <div class="first-letter">December 21 - Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer.</div>
            <div class="first-letter">November 30 - Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH.</div>
            <div class="first-letter"> November 16 - FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study.</div>
            <div class="first-letter">September 29 - All Endpoints Met in Drug-Drug Interaction Study with CRV431.</div>
            <div class="first-letter">July 13 - Announces Positive Topline Data from P2A AMBITION NASH Trial: All Primary Endpoints Achieved.</div>
            <div class="first-letter">June 9 - Hepion Pharmaceuticals to be Added to the Russell Microcap® Index.</div>
            <div class="first-letter">May 6 - Completes Final Patient Recruitment in P2A AMBITION Clinical Trial of CRV431 for the Treatment of Advanced NASH.</div>
            <div class="first-letter">March 23 - DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of CRV431.</div>
            <div class="first-letter">February 12 - Announces Proposed Public Offering of Common Stock.</div>
            <!-- Break -->
            <br><h3>2020</h3><br>
            <div class="first-letter">December 29 - Announces Positive Top Line Data: Low Dose CRV431 in P2A AMBITION Clinical Trial for Treatment of Advanced NASH.</div>
            <div class="first-letter">December 10 - Completes 75 mg CRV431 Dosing, Initiates 225 mg Dosing in P2A AMBITION Clinical Trial for NASH.</div>
            <div class="first-letter">December 2 - CRV431 Demonstrates Additional Potential Advantage in Liver Disease.</div>
            <div class="first-letter">November 24 - Hepion Pharmaceuticals Prices Public Offering.</div>
            <div class="first-letter">October 5 - Introduces Proprietary A.I. Platform for Drug Development & Announces Creation of Clinical Pharmacology Analytics Team.</div>
            <div class="first-letter">September 17 - Positive Activity of CRV431 Against Coronavirus SARS-2 in Study Conducted by the National Institute of Allergy and Infectious Diseases.</div>
            <div class="first-letter">September 1 - Completes Final Dosing in P1B Multiple Ascending Dose Study of CRV431.</div>
            <div class="first-letter">August 12 - Announces Publication of Preclinical Study Evaluating CRV431's Antiviral Properties.</div>
            <div class="first-letter">August 5 - Announces First NASH Patient Dosed with CRV431 in P2 AMBITION Clinical Trial.</div>
            <div class="first-letter">July 7 - Announces Preclinical Data Supporting Novel Two-Pronged Approach to Treating COVID-19 with CRV431.</div>
            <div class="first-letter">June 29 - Announces Advancement to Final Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431.</div>
            <div class="first-letter">June 22 - CRV431 Demonstrates Efficacy in Kidney Fibrosis.</div>
            <div class="first-letter">May 20 - Announces Advancement to Fourth Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431.</div>
            <div class="first-letter">May 20 - CRV431 the First Cyclophilin Inhibitor to Advance to Phase 2 Trial for NASH Fibrosis.</div>
            <div class="first-letter">March 12 - CRV431 Demonstrates Efficacy in Human Idiopathic Pulmonary Fibrosis Translational Research Study.</div>
            <div class="first-letter">February 19 - Anti-Fibrotic Activity of CRV431 Shows Potential to Extend to Multiple Organs and Fibrotic Diseases.</div>
            <div class="first-letter">February 12 - Announces Advancement to Third Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431.</div>
            <div class="first-letter">January 28 - CRV431, Demonstrates Superior Antifibrotic Efficacy in Expanded Human Liver Study.</div>
        </div>
    </section>
</body>

</html>